Periostin is a highly conserved functional protein, which plays an important role in the process of vascular injury and myocardial fibrosis. In recent years, there have been more and more studies on the peirostin protein in cardiovascular diseases. This article summarizes the present understanding regarding the relationship between periostin and cardiovascular disease.

Objective To explore the protective effects on radiation injury of guinea pigs 'cochlea by sul-fotanshinoneⅡA sodium injection. Methods 20 guinea pigs(40 ears)were randomly divided into control group , radiotherapy(RT)group,radiotherapy and drug(RT+D)group and drug(D)group. The guinea pigs in the RT+D group and the D group were injected intraperitoneally with tanshinone on 2 days before the irradiation and last-ed for 7 days,while the guinea pigs in the control group and the RT group were injected intrapertoneally with equal amount of physiological saline at the same time. All the guinea pigs underwent audiologic test with DPOAE and ABR at different time points before and after the irradiation,which were d0,d7 and d8w. All pigs were sacrificed after the completion of the audiologic experimental and for histologic observation. Results After the irradiation, the DPOAE amplitudes of the guinea pigs in both RT group(F=1134.064,P<0.001)and RT+D group(F=664.185,P < 0.001)decreased significantly,but the range in the RT + D group was lower than in the RT group (P<0.001). The ABR threshold of the guinea pigs raised significantly in the RT group(F=12.228,P=0.002 <0.05),but not in the RT+D group(F=2.867,P=0.102>0.05). Histological examination showed that the dam-age degree of hair cells,stria vascularis and the spiral ganglion cells in the organ of Corti of the guinea pigs were lower than in the RT + D group,but higher in the RT group. Conclusion Sulfotanshinone ⅡA sodium injection can provide protection against radiation injury of guinea cochlea.

Objective:To analysis the construction of the world's top PhaseⅠclinical trial registration agencies, compare their size, composition, operation and funding, to provide further reference for the construction of clinical trial agency in China.Methods:Search for PhaseⅠclinical trial research agencies by region on clinicaltrials.gov. Collecting information about the agency’s management, staffing, implementation in Asia, America and Europe. Descriptive analysis was carried out to explore the type, proportion and operation among different regions, the organizational structure, operational management and effectiveness of each agency from different regions were compared.Results:The United States, Europe and East Asia are dense areas of PhaseⅠclinical research around the world. The types of agencies in the United States, Britain, France, Germany, South Korea, Japan, and Israel are mainly enterprises. Among other types of agencies, the organizational models are diversified. The agencies have different spatial distances from medical institutions, but possess relatively consistent scale and institutional operation. All the agencies have a stable source of funding.Conclusions:In order to strengthen the construction of clinical trial agencies in China, we should speed up the establishment of a close connection mechanism to promote deep cooperation in clinical trials. Control the construction scale and maintain stable input of the agency. Meanwhile, establish and strengthen international exchanges and cooperation.